Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma

In the absence of a driver mutation, chemotherapy is the standard treatment option as first- and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large number of patients are suitable for post second-line therapies, the quality and quantity of the available drugs in this...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Shen-Cun, Zhang, Hai-Tao, Zhang, Ying-Ming, Xie, Wei-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261838/
https://www.ncbi.nlm.nih.gov/pubmed/28176910
http://dx.doi.org/10.2147/OTT.S126613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261838/
https://www.ncbi.nlm.nih.gov/pubmed/28176910
http://dx.doi.org/10.2147/OTT.S126613

Ejemplares similares